Rui Tato Marinho

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Péter Ferenci, David Bernstein, Jacob Lalezari et al. · New England Journal of Medicine · 2014 · 695 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

36th International Symposium on Intensive Care and Emergency Medicine

R. M. Bateman, Michael D. Sharpe, Justin E. Jagger et al. · Critical Care · 2016 · 521 citations · Full text

Life Sciences, Pharmacology, Physiology +17

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Stefan Zeuzem, Ira M. Jacobson, Tolga Baykal et al. · New England Journal of Medicine · 2014 · 519 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Homie Razavi, Imam Waked, Christoph Sarrazin et al. · Journal of Viral Hepatitis · 2014 · 484 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +16

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Tarik Asselah, Kris V. Kowdley, Neddie Zadeikis et al. · Clinical Gastroenterology and Hepatology · 2017 · 230 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17